Cargando…

The Present and Future of Optic Pathway Glioma Therapy

Optic pathway gliomas (OPGs) encompass two distinct categories: benign pediatric gliomas, which are characterized by favorable prognosis, and malignant adult gliomas, which are aggressive cancers associated with a poor outcome. Our review aims to explore the established standards of care for both ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal Bello, Simone, Martinuzzi, Deborah, Tereshko, Yan, Veritti, Daniele, Sarao, Valentina, Gigli, Gian Luigi, Lanzetta, Paolo, Valente, Mariarosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572241/
https://www.ncbi.nlm.nih.gov/pubmed/37830595
http://dx.doi.org/10.3390/cells12192380
_version_ 1785120188862038016
author Dal Bello, Simone
Martinuzzi, Deborah
Tereshko, Yan
Veritti, Daniele
Sarao, Valentina
Gigli, Gian Luigi
Lanzetta, Paolo
Valente, Mariarosaria
author_facet Dal Bello, Simone
Martinuzzi, Deborah
Tereshko, Yan
Veritti, Daniele
Sarao, Valentina
Gigli, Gian Luigi
Lanzetta, Paolo
Valente, Mariarosaria
author_sort Dal Bello, Simone
collection PubMed
description Optic pathway gliomas (OPGs) encompass two distinct categories: benign pediatric gliomas, which are characterized by favorable prognosis, and malignant adult gliomas, which are aggressive cancers associated with a poor outcome. Our review aims to explore the established standards of care for both types of tumors, highlight the emerging therapeutic strategies for OPG treatment, and propose potential alternative therapies that, while originally studied in a broader glioma context, may hold promise for OPGs pending further investigation. These potential therapies encompass immunotherapy approaches, molecular-targeted therapy, modulation of the tumor microenvironment, nanotechnologies, magnetic hyperthermia therapy, cyberKnife, cannabinoids, and the ketogenic diet. Restoring visual function is a significant challenge in cases where optic nerve damage has occurred due to the tumor or its therapeutic interventions. Numerous approaches, particularly those involving stem cells, are currently being investigated as potential facilitators of visual recovery in these patients.
format Online
Article
Text
id pubmed-10572241
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105722412023-10-14 The Present and Future of Optic Pathway Glioma Therapy Dal Bello, Simone Martinuzzi, Deborah Tereshko, Yan Veritti, Daniele Sarao, Valentina Gigli, Gian Luigi Lanzetta, Paolo Valente, Mariarosaria Cells Review Optic pathway gliomas (OPGs) encompass two distinct categories: benign pediatric gliomas, which are characterized by favorable prognosis, and malignant adult gliomas, which are aggressive cancers associated with a poor outcome. Our review aims to explore the established standards of care for both types of tumors, highlight the emerging therapeutic strategies for OPG treatment, and propose potential alternative therapies that, while originally studied in a broader glioma context, may hold promise for OPGs pending further investigation. These potential therapies encompass immunotherapy approaches, molecular-targeted therapy, modulation of the tumor microenvironment, nanotechnologies, magnetic hyperthermia therapy, cyberKnife, cannabinoids, and the ketogenic diet. Restoring visual function is a significant challenge in cases where optic nerve damage has occurred due to the tumor or its therapeutic interventions. Numerous approaches, particularly those involving stem cells, are currently being investigated as potential facilitators of visual recovery in these patients. MDPI 2023-09-29 /pmc/articles/PMC10572241/ /pubmed/37830595 http://dx.doi.org/10.3390/cells12192380 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dal Bello, Simone
Martinuzzi, Deborah
Tereshko, Yan
Veritti, Daniele
Sarao, Valentina
Gigli, Gian Luigi
Lanzetta, Paolo
Valente, Mariarosaria
The Present and Future of Optic Pathway Glioma Therapy
title The Present and Future of Optic Pathway Glioma Therapy
title_full The Present and Future of Optic Pathway Glioma Therapy
title_fullStr The Present and Future of Optic Pathway Glioma Therapy
title_full_unstemmed The Present and Future of Optic Pathway Glioma Therapy
title_short The Present and Future of Optic Pathway Glioma Therapy
title_sort present and future of optic pathway glioma therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572241/
https://www.ncbi.nlm.nih.gov/pubmed/37830595
http://dx.doi.org/10.3390/cells12192380
work_keys_str_mv AT dalbellosimone thepresentandfutureofopticpathwaygliomatherapy
AT martinuzzideborah thepresentandfutureofopticpathwaygliomatherapy
AT tereshkoyan thepresentandfutureofopticpathwaygliomatherapy
AT verittidaniele thepresentandfutureofopticpathwaygliomatherapy
AT saraovalentina thepresentandfutureofopticpathwaygliomatherapy
AT gigligianluigi thepresentandfutureofopticpathwaygliomatherapy
AT lanzettapaolo thepresentandfutureofopticpathwaygliomatherapy
AT valentemariarosaria thepresentandfutureofopticpathwaygliomatherapy
AT dalbellosimone presentandfutureofopticpathwaygliomatherapy
AT martinuzzideborah presentandfutureofopticpathwaygliomatherapy
AT tereshkoyan presentandfutureofopticpathwaygliomatherapy
AT verittidaniele presentandfutureofopticpathwaygliomatherapy
AT saraovalentina presentandfutureofopticpathwaygliomatherapy
AT gigligianluigi presentandfutureofopticpathwaygliomatherapy
AT lanzettapaolo presentandfutureofopticpathwaygliomatherapy
AT valentemariarosaria presentandfutureofopticpathwaygliomatherapy